Inhibikase Therapeutics Inc (IKT)
Healthcare
Biotechnology
2.20 $
+1.4%
vs. previous close
Closing price · As of: 3. Aug 2026
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Inhibikase Therapeutics Inc (IKT) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 07/29/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View report → |
| 07/28/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document → |
| 07/23/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Regulation FD Disclosure; Financial Statements and Exhibits | View report → |
| 07/17/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document → |
| 07/14/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Other Events; Financial Statements and Exhibits | View report → |
Showing the 100 most recent filings of the selected type.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.